SEGMENTS

3 Months Ended

Mar. 31, 2023

SEGMENTS [Abstract]

SEGMENTS

11. SEGMENTS

The Company is engaged in the manufacture, marketing and development of specialty plasma-derived biologics. The Company’s ADMA BioManufacturing segment reflects the Company’s immunoglobulin manufacturing, commercial and development operations in Boca Raton, FL.  The Plasma Collection Centers segment consists of ten operational plasma collection facilities located throughout the U.S., eight of which currently hold FDA licenses. The Corporate segment includes general and administrative overhead expenses. The Company defines its segments as those business units whose operating results are regularly reviewed by the chief operating decision maker (“CODM”) to analyze performance and allocate resources. The Company’s CODM is its President and Chief Executive Officer. Summarized financial information concerning reportable segments is shown in the following tables:

Three Months Ended March 31, 2023
	ADMA			Plasma Collection
	BioManufacturing			Centers			Corporate			Consolidated
Revenues	$	49,576,935		$	7,300,891		$	35,708		$	56,913,534
Cost of product revenue		33,933,782			6,466,762			-			40,400,544
Income (loss) from operations		5,476,441			(946,334	)		(5,343,425	)		(813,318	)
Interest and other expense, net		(23,779	)		(227	)		(5,951,491	)		(5,975,497	)
Net income (loss)		5,452,662			(946,561	)		(11,294,916	)		(6,788,815	)
Capital expenditures		452,032			1,492,564			-			1,944,596
Depreciation and amortization expense		1,292,608			740,357			-			2,032,965
Total assets		234,894,891			38,853,662			67,038,989			340,787,542

Three Months Ended March 31, 2022
	ADMA			Plasma Collection
	BioManufacturing			Centers			Corporate			Consolidated
Revenues	$	25,728,625		$	3,338,760		$	35,708		$	29,103,093
Cost of product revenue		22,213,781			3,227,265			-			25,441,046
Loss from operations		(4,442,684	)		(3,863,094	)		(6,509,288	)		(14,815,066	)
Interest and other expense, net		(49,267	)		(729	)		(3,472,854	)		(3,522,850	)
Loss on extinguishment of debt		-			-			(6,669,941	)		(6,669,941	)
Net loss		(4,491,951	)		(3,863,823	)		(16,652,083	)		(25,007,857	)
Capital expenditures		1,310,379			1,531,706			-			2,842,085
Depreciation and amortization expense		1,111,951			477,503			763			1,590,217
Total assets		214,150,322			32,568,911			61,313,259			308,032,492

Net revenues according to geographic area, based on the location of where the product is shipped, is as follows:

	Three Months Ended March 31,
	2023		2022
United States	$	52,694,723	$	27,316,151
International		4,218,811		1,786,942
Total revenues	$	56,913,534	$	29,103,093